Some preclinical studies have suggested that CDK4/6i, namely palbociclib, can be a substrate for the ABCB1 and/or ABCG2 transporters, which could inclusively affect their ability to cross the blood–brain barrier [168,216] and decrease anticancer efficacy in cancer cells overexpressing the ABCB1 [169]. Here, CDK4 is linked to cancer.